Alunbrig (brigatinib) — Cigna
Peripheral T-Cell Lymphomas (Anaplastic Large Cell Lymphoma, ALK-positive)
Initial criteria
- Patient age ≥ 18 years
- Patient has anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL)
Approval duration
1 year